A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.

Lin28 enhances tissue repair by reprogramming cellular metabolism. Cell (2013) 3.08

The role of senescent cells in ageing. Nature (2014) 3.03

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74

Cellular senescence and its effector programs. Genes Dev (2014) 2.37

Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol (2014) 2.36

The Emerging Hallmarks of Cancer Metabolism. Cell Metab (2016) 2.32

Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov (2013) 2.08

Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest (2014) 1.58

Exploiting the bad eating habits of Ras-driven cancers. Genes Dev (2013) 1.45

Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming. Cancer Cell (2016) 1.41

Sirtuins: guardians of mammalian healthspan. Trends Genet (2014) 1.36

The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci (2016) 1.36

Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol (2014) 1.35

A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol Cell (2014) 1.34

The pyruvate dehydrogenase complexes: structure-based function and regulation. J Biol Chem (2014) 1.31

Mitochondria are required for pro-ageing features of the senescent phenotype. EMBO J (2016) 1.27

Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget (2013) 1.24

Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep (2014) 1.21

Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17

Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab (2015) 1.17

Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest (2013) 1.12

Aging-Induced Stem Cell Mutations as Drivers for Disease and Cancer. Cell Stem Cell (2015) 1.11

Mitochondrial effectors of cellular senescence: beyond the free radical theory of aging. Aging Cell (2014) 1.11

Mitochondrial sirtuins and their relationships with metabolic disease and cancer. Antioxid Redox Signal (2015) 1.09

Adaptive stress signaling in targeted cancer therapy resistance. Oncogene (2015) 1.07

Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. Mol Cell (2016) 1.07

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature (2016) 1.06

Low abundance of the matrix arm of complex I in mitochondria predicts longevity in mice. Nat Commun (2014) 1.05

Fumarate induces redox-dependent senescence by modifying glutathione metabolism. Nat Commun (2015) 1.04

The Mitochondrial Basis of Aging. Mol Cell (2016) 1.02

Tumor suppressor WWOX regulates glucose metabolism via HIF1α modulation. Cell Death Differ (2014) 1.00

Phenotype switching in melanoma: implications for progression and therapy. Front Oncol (2015) 1.00

Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res (2014) 0.98

Regulation of mitochondrial pyruvate uptake by alternative pyruvate carrier complexes. EMBO J (2015) 0.98

ATM couples replication stress and metabolic reprogramming during cellular senescence. Cell Rep (2015) 0.98

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma. Mol Syst Biol (2014) 0.97

Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers. Cancer Discov (2014) 0.94

p16(Ink4a)-induced senescence of pancreatic beta cells enhances insulin secretion. Nat Med (2016) 0.94

Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells. Cancer Metab (2015) 0.94

The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis. Cell Cycle (2014) 0.94

Hypoxia-resistant profile implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets. Cell Cycle (2013) 0.94

Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res (2013) 0.93

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest (2016) 0.93

In vitro models of the metastatic cascade: from local invasion to extravasation. Drug Discov Today (2013) 0.91

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis. Am J Respir Crit Care Med (2015) 0.91

Selective Vulnerability of Cancer Cells by Inhibition of Ca(2+) Transfer from Endoplasmic Reticulum to Mitochondria. Cell Rep (2016) 0.90

Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism. J Immunol (2015) 0.90

Quantitation and Identification of Thousands of Human Proteoforms below 30 kDa. J Proteome Res (2016) 0.90

Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket. J Biol Chem (2013) 0.88

The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing. Sci Rep (2015) 0.88

c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate. J Biol Chem (2014) 0.88

Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children. J Clin Pharmacol (2014) 0.87

Telomeres, oxidative stress and inflammatory factors: partners in cellular senescence? Longev Healthspan (2014) 0.87

Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition. J Transl Med (2014) 0.86

Hypoxia and metabolic adaptation of cancer cells. Oncogenesis (2016) 0.86

Resveratrol restores sirtuin 1 (SIRT1) activity and pyruvate dehydrogenase kinase 1 (PDK1) expression after hemorrhagic injury in a rat model. Mol Med (2014) 0.86

From Ancient Pathways to Aging Cells-Connecting Metabolism and Cellular Senescence. Cell Metab (2016) 0.86

Retinoblastoma protein promotes oxidative phosphorylation through upregulation of glycolytic genes in oncogene-induced senescent cells. Aging Cell (2015) 0.85

Cellular senescence and protein degradation: breaking down cancer. Cell Cycle (2014) 0.85

Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep (2016) 0.84

Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence. Cell Death Dis (2014) 0.84

VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells. Oncotarget (2014) 0.83

Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis. Neuro Oncol (2015) 0.83

Novel therapeutic targets of tumor metabolism. Cancer J (2015) 0.82

Bonded Cumomer Analysis of Human Melanoma Metabolism Monitored by 13C NMR Spectroscopy of Perfused Tumor Cells. J Biol Chem (2015) 0.81

Pyruvate and Metabolic Flexibility: Illuminating a Path Toward Selective Cancer Therapies. Trends Biochem Sci (2016) 0.81

Chromatin maintenance and dynamics in senescence: a spotlight on SAHF formation and the epigenome of senescent cells. Chromosoma (2014) 0.81

Elucidation of the interaction loci of the human pyruvate dehydrogenase complex E2·E3BP core with pyruvate dehydrogenase kinase 1 and kinase 2 by H/D exchange mass spectrometry and nuclear magnetic resonance. Biochemistry (2014) 0.80

Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming. Sci Rep (2016) 0.80

Glucose-independent Acetate Metabolism Promotes Melanoma Cell Survival and Tumor Growth. J Biol Chem (2016) 0.80

Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target? Int J Biol Sci (2015) 0.80

Regulation of Metabolic Activity by p53. Metabolites (2017) 0.79

Just like the rest of evolution in Mother Nature, the evolution of cancers may be driven by natural selection, and not by haphazard mutations. Oncoscience (2014) 0.79

Pyruvate as a pivot point for oncogene-induced senescence. Cell (2013) 0.79

Glucose substitution prolongs maintenance of energy homeostasis and lifespan of telomere dysfunctional mice. Nat Commun (2014) 0.79

Glucose Oxidation Is Critical for CD4+ T Cell Activation in a Mouse Model of Systemic Lupus Erythematosus. J Immunol (2015) 0.79

Golgi N-glycan branching N-acetylglucosaminyltransferases I, V and VI promote nutrient uptake and metabolism. Glycobiology (2014) 0.79

Warburg-like Glycolysis and Lactate Shuttle in Mouse Decidua during Early Pregnancy. J Biol Chem (2015) 0.79

Oncogene-directed alterations in cancer cell metabolism. Trends Cancer (2016) 0.78

Disruptive chemicals, senescence and immortality. Carcinogenesis (2015) 0.78

Phosphoproteome dynamics in onset and maintenance of oncogene-induced senescence. Mol Cell Proteomics (2014) 0.78

p53 and regulation of tumor metabolism. J Carcinog (2013) 0.78

Linking Cancer Metabolism to DNA Repair and Accelerated Senescence. Mol Cancer Res (2015) 0.78

(13)C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism. Front Oncol (2016) 0.78

Effect of fatty acids on human bone marrow mesenchymal stem cell energy metabolism and survival. PLoS One (2015) 0.78

Mitochondrial Ca(2+) Remodeling is a Prime Factor in Oncogenic Behavior. Front Oncol (2015) 0.78

The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation. Mol Cancer Ther (2015) 0.77

3D functional and perfusable microvascular networks for organotypic microfluidic models. J Mater Sci Mater Med (2015) 0.77

Mitochondrial Dysfunction and Disturbed Coherence: Gate to Cancer. Pharmaceuticals (Basel) (2015) 0.77

Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1α in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis. Cancer Sci (2014) 0.77

Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer. Curr Metabolomics (2014) 0.77

ETS Proto-oncogene 1 Transcriptionally Up-regulates the Cholangiocyte Senescence-associated Protein Cyclin-dependent Kinase Inhibitor 2A. J Biol Chem (2017) 0.77

Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial. Laryngoscope (2017) 0.76

Demystifying the role of mitochondria in senescence. Mol Cell Oncol (2016) 0.76

Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics. Int J Cell Biol (2015) 0.76

Metabolism under the spotlight in senescence. Pigment Cell Melanoma Res (2013) 0.76

Metabolic rewiring in melanoma. Oncogene (2016) 0.76

Metabolic vulnerability in melanoma: a ME2 (me too) story. J Invest Dermatol (2015) 0.76

Metabolic alterations accompanying oncogene-induced senescence. Mol Cell Oncol (2014) 0.76

p53 Enables metabolic fitness and self-renewal of nephron progenitor cells. Development (2015) 0.76

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41

BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87

Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell (2006) 9.80

Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell (2008) 9.22

Intrinsic tumour suppression. Nature (2004) 8.73

The essence of senescence. Genes Dev (2010) 8.21

Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev (2008) 7.87

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81

Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34

Targeting metabolic transformation for cancer therapy. Nat Rev Cancer (2010) 5.90

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07

Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76

Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature (2011) 4.32

Oncogene-induced cell senescence--halting on the road to cancer. N Engl J Med (2006) 3.39

Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature (2012) 3.01

Quiescent fibroblasts exhibit high metabolic activity. PLoS Biol (2010) 2.94

Molecular biology and biochemistry of pyruvate dehydrogenase complexes. FASEB J (1990) 2.86

Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans (2003) 2.81

Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. Mol Cell (2009) 2.58

Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell (2010) 2.50

Replicative senescence: an old lives' tale? Cell (1996) 2.32

Regulation of the pyruvate dehydrogenase complex. Biochem Soc Trans (2006) 2.28

The mammalian pyruvate dehydrogenase complex: structure and regulation. Rev Physiol Biochem Pharmacol (1983) 2.13

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev (2012) 2.06

Suppressing cancer: the importance of being senescent. Science (2005) 2.03

Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One (2011) 1.86

Vemurafenib. Nat Rev Drug Discov (2011) 1.68

Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog Nucleic Acid Res Mol Biol (2001) 1.68

Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem J (2001) 1.60

Complementation of hypopigmentation in p-mutant (pink-eyed dilution) mouse melanocytes by normal human P cDNA, and defective complementation by OCA2 mutant sequences. J Invest Dermatol (1997) 1.29

BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87

TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell (2006) 11.85

Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell (2005) 9.33

Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell (2008) 9.22

The essence of senescence. Genes Dev (2010) 8.21

Transcriptional regulation of protein complexes within and across species. Proc Natl Acad Sci U S A (2007) 7.07

Targeting metabolic transformation for cancer therapy. Nat Rev Cancer (2010) 5.90

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79

Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer (2009) 5.02

Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature (2004) 4.53

Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature (2011) 4.32

The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol (2005) 4.29

KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer (2006) 4.14

Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature (2012) 3.77

Associating genes and protein complexes with disease via network propagation. PLoS Comput Biol (2010) 3.65

Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol (2011) 3.65

RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell (2007) 3.47

Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol (2007) 3.33

Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol (2010) 2.88

Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell (2012) 2.82

Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. Mol Syst Biol (2010) 2.60

Metastasis mechanisms. Biochim Biophys Acta (2009) 2.51

Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31

Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol (2008) 2.30

Mitochondria in cancer: not just innocent bystanders. Semin Cancer Biol (2008) 2.23

Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12

Metabolic transformation in cancer. Carcinogenesis (2009) 2.07

Cardiolipin: setting the beat of apoptosis. Apoptosis (2007) 2.06

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev (2012) 2.06

Cardiolipin provides an essential activating platform for caspase-8 on mitochondria. J Cell Biol (2008) 2.06

Inborn and acquired metabolic defects in cancer. J Mol Med (Berl) (2011) 2.06

Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res (2009) 2.04

M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol (2011) 2.02

Raf-1 addiction in Ras-induced skin carcinogenesis. Cancer Cell (2009) 1.99

High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93

The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93

mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab (2013) 1.91

Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90

Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem Sci (2012) 1.89

Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One (2011) 1.86

A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol (2009) 1.74

Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discov Today (2002) 1.74

K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res (2005) 1.73

Reconstruction of Arabidopsis metabolic network models accounting for subcellular compartmentalization and tissue-specificity. Proc Natl Acad Sci U S A (2011) 1.68

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67

Cardiolipin acts as a mitochondrial signalling platform to launch apoptosis. Biochim Biophys Acta (2009) 1.66

Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS Comput Biol (2011) 1.66

Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66

Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53. Mol Cell (2013) 1.65

Integrating quantitative proteomics and metabolomics with a genome-scale metabolic network model. Bioinformatics (2010) 1.65

SPINE: a framework for signaling-regulatory pathway inference from cause-effect experiments. Bioinformatics (2007) 1.60

E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell (2002) 1.59

Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res (2010) 1.59

A direct comparison of protein interaction confidence assignment schemes. BMC Bioinformatics (2006) 1.56

Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol (2013) 1.56

Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res (2007) 1.56

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res (2008) 1.54

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol (2007) 1.54

Predicting metabolic engineering knockout strategies for chemical production: accounting for competing pathways. Bioinformatics (2009) 1.51

Mitochondria-derived reactive oxygen species mediate blue light-induced death of retinal pigment epithelial cells. Photochem Photobiol (2004) 1.50

Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells. J Biol Chem (2002) 1.47

Translation efficiency in humans: tissue specificity, global optimization and differences between developmental stages. Nucleic Acids Res (2010) 1.42

Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res (2003) 1.40

Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res (2005) 1.38

The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab (2013) 1.36

Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol (2013) 1.35

From E-MAPs to module maps: dissecting quantitative genetic interactions using physical interactions. Mol Syst Biol (2008) 1.35

Targeting cell cycle regulation in cancer therapy. Pharmacol Ther (2013) 1.32

iMAT: an integrative metabolic analysis tool. Bioinformatics (2010) 1.32

QNet: a tool for querying protein interaction networks. J Comput Biol (2008) 1.32

Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30

Deregulating EMT and senescence: double impact by a single twist. Cancer Cell (2008) 1.29

Epitope mapping using combinatorial phage-display libraries: a graph-based algorithm. Nucleic Acids Res (2006) 1.29

Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res (2013) 1.28

Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28

Essential role of B-Raf in ERK activation during extraembryonic development. Proc Natl Acad Sci U S A (2006) 1.28

Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res (2009) 1.27

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26

Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). Blood (2003) 1.26

Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One (2011) 1.26

A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer (2010) 1.25

Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res (2011) 1.24

ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts. Cell Cycle (2006) 1.24

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 1.23

Therapeutic cancer vaccines. J Clin Invest (2015) 1.23

Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res (2002) 1.22

Reactive oxygen species production by forward and reverse electron fluxes in the mitochondrial respiratory chain. PLoS Comput Biol (2011) 1.21